Short answer
Boston Scientific (BSX) filed its Q2 2025 10-Q quarterly report on Aug 1, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $5.1B (up 22.8% year over year) with net income of $797M.
Q2 2025 key financials · XBRL
- Revenue
- $5.1B
- +22.8% YoY · +8.5% QoQ
- Net income
- $797M
- +146.0% YoY · +18.2% QoQ
- Operating margin
- 16.2%
- Gross margin
- 67.6%
- EPS (diluted)
- $0.53
- +140.9% YoY · +17.8% QoQ
Source: XBRL data from the Boston Scientific (BSX) Q2 2025 10-Q on SEC EDGAR. USD.
Boston Scientific Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin % figures disclosed in excerpt
- Restructuring charges related to discontinuing ACURATE neo2 and ACURATE Prime Aortic Valve Systems sales noted
- No cash position, operating cash flow, or capital deployment changes detailed in excerpt
- Forward-looking statements highlight risks and uncertainties without updated guidance or near-term outlook specifics
Risk Factors
- No new or changed risk factors disclosed this quarter; risk section references most recent 10-K
- Carried-forward regulatory risk: ongoing compliance with Sarbanes-Oxley Act Sections 302 and 906 certifications by CEO and CFO
- Operational risk: reliance on performance-based annual bonus plan for 2025 could impact employee retention and motivation
- Legal risk: no Rule 10b5-1 trading arrangements adopted or terminated by directors/officers in Q2 2025, limiting insider trading risk changes
- Financial risk: subsidiary issuer guarantees outstanding securities, potentially affecting liquidity and credit exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Boston Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.